Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.54 +5.8%	$2.08	$0.77 ▼ $4.08	$331.88M	1.42	953,381 shs	683,614 shs
ETON Eton Pharmaceuticals	$13.51 -0.4%	$16.68	$3.19 ▼ $21.48	$363.91M	1.28	228,900 shs	371,460 shs
SAVA Cassava Sciences	$1.89 -5.0%	$1.88	$1.15 ▼ $42.20	$96.13M	-2	3.01 million shs	1.12 million shs
ZYBT Zhengye Biotechnology	$7.43 -20.1%	$8.80	$3.50 ▼ $14.30	$438.65M	N/A	498,264 shs	460,455 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	+5.83%	+7.17%	+21.53%	+17.59%	+130.91%
ETON Eton Pharmaceuticals	-0.44%	-4.66%	-31.80%	-1.67%	+304.49%
SAVA Cassava Sciences	-5.03%	-7.80%	-10.43%	-0.53%	-90.56%
ZYBT Zhengye Biotechnology	-20.11%	+3.48%	-12.90%	-9.39%	+742,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	3.2986 of 5 stars	4.6	1.0	0.0	0.0	1.5	5.0	0.0
ETON Eton Pharmaceuticals	2.708 of 5 stars	3.5	3.0	0.0	0.0	2.4	1.7	0.6
SAVA Cassava Sciences	3.9831 of 5 stars	3.3	3.0	0.0	4.7	1.1	0.8	1.3
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.11	Buy	$13.13	416.73% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	119.59% Upside
SAVA Cassava Sciences	2.50	Moderate Buy	$54.50	2,783.60% Upside
ZYBT Zhengye Biotechnology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SAVA, ETON, CMPX, and ZYBT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/14/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$26.00 ➝ $28.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/4/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $24.00
4/2/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/2/2025	CMPX Compass Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $6.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	413.21	N/A	N/A	$0.91 per share	2.79
ETON Eton Pharmaceuticals	$39.01M	9.29	N/A	N/A	$0.94 per share	14.37
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.03 per share	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	27.02	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
SAVA Cassava Sciences	-$24.34M	-$1.50	N/A	N/A	N/A	N/A	-87.72%	-72.05%	8/6/2025 (Estimated)
ZYBT Zhengye Biotechnology	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SAVA, ETON, CMPX, and ZYBT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/8/2025	Q1 2025	SAVA Cassava Sciences	N/A	-$0.48	N/A	-$0.48	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	8.33	8.33
ETON Eton Pharmaceuticals	1.23	1.97	1.43
SAVA Cassava Sciences	N/A	9.08	9.08
ZYBT Zhengye Biotechnology	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
ETON Eton Pharmaceuticals	27.86%
SAVA Cassava Sciences	38.05%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	29.80%
ETON Eton Pharmaceuticals	14.89%
SAVA Cassava Sciences	12.20%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.83 million	Optionable
SAVA Cassava Sciences	30	48.31 million	42.41 million	Optionable
ZYBT Zhengye Biotechnology	278	47.17 million	N/A	N/A

SAVA, ETON, CMPX, and ZYBT Headlines

Recent News About These Companies

Zhengye Biotechnology Holding Ltd

June 21 at 7:32 PM | morningstar.com

Zhengye Biotechnology (NASDAQ:ZYBT) Trading Down 6% - Time to Sell?

June 7, 2025 | marketbeat.com

ZYBT Zhengye Biotechnology Holding Limited

May 30, 2025 | seekingalpha.com

Zhengye Biotechnology faces NASDAQ compliance issue

May 24, 2025 | investing.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing Requirements

May 23, 2025 | quiverquant.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

May 23, 2025 | globenewswire.com

Should We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?

April 7, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Ltd.

April 3, 2025 | wsj.com

Zhengye Biotechnology Holding Limited (ZYBT)

March 27, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

January 14, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

January 8, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

January 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SAVA, ETON, CMPX, and ZYBT Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$2.54 +0.14 (+5.83%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$2.52 -0.02 (-0.59%)

As of 08:30 AM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Eton Pharmaceuticals NASDAQ:ETON

$13.51 -0.06 (-0.44%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$13.28 -0.23 (-1.67%)

As of 08:05 AM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Cassava Sciences NASDAQ:SAVA

$1.89 -0.10 (-5.03%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$1.92 +0.04 (+1.85%)

As of 08:40 AM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Zhengye Biotechnology NASDAQ:ZYBT

$7.43 -1.87 (-20.11%)

As of 06/23/2025 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time